1. Academic Validation
  2. Anti-angiogenic peptides identified in thrombospondin type I domains

Anti-angiogenic peptides identified in thrombospondin type I domains

  • Biochem Biophys Res Commun. 2007 Jul 20;359(1):63-9. doi: 10.1016/j.bbrc.2007.05.041.
Emmanouil D Karagiannis 1 Aleksander S Popel
Affiliations

Affiliation

  • 1 Department of Biomedical Engineering, Johns Hopkins University, School of Medicine, 613 Traylor Building, 720 Rultland Avenue, Baltimore, MD 21205, USA.
Abstract

Thrombospondin 1, the prototypical protein of the thrombospondin protein family, is a potent endogenous inhibitor of angiogenesis. Although the effects of the thrombospondin 1 on neovascularization have been well studied, little is known about the anti-angiogenic potency of other proteins or peptide fragments derived from the proteins in this family. Here we identify a set of 18 novel, anti-angiogenic 17- to 20-amino acid Peptides that are derived from proteins containing type I thrombospondin motifs. We have named these Peptides adamtsostatin-4, adamtsostatin-16, adamtsostatin-18, cartilostatin-1, cartilostatin-2, fibulostatin-6.2, fibulostatin-6.3, papilostatin-1, papilostatin-2, properdistatin, scospondistatin, semastatin-5A.1, semastatin-5A.2, semastatin-5B, thrombostatin containing-1, thrombostatin contaning-3, thrombostatin contaning-6, and wispostatin-1 to reflect their origin. We further demonstrate that these Peptides inhibit the proliferation and migration of human umbilical vein endothelial cells in vitro. The anti-proliferative and anti-migratory properties of the identified Peptides may be important in maintaining angiogenic homeostasis in vivo and make these Peptides suitable candidates for use as anti-angiogenic pharmaceutical agents in numerous therapeutic applications.

Figures
Products